TSE:GUD
Knight Therapeutics (GUD.TO)
Financials 
Technical Analysis 
Sep 3, 2026, 12:00 amThis summary was created by AI, based on 3 opinions in the last 12 months.
Knight Therapeutics (GUD-T) has garnered mixed reviews from experts, reflecting a complex outlook for the company's future. The stock is perceived as undervalued, with the market seeking more consistency in earnings to support its strategy of acquiring 'orphaned' drugs. However, there is caution among investors, with some believing that they may face stagnation while holding this stock. Although the company has made progress, particularly in its Brazilian operations, the stock has experienced volatility, hovering between $5.75 and $6. Analysts note the presence of oversold indicators, but there are no guarantees for a price rebound. Thus, potential investors must weigh their options carefully, considering the company's current position in the healthcare sector.
Only on the market a couple of months. There are only two people in the company. A drug has just been approved. Thinks it will be very exciting.
Michael Smedley'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Got hit today because they are issuing warrants. Good opportunity to buy in right now. Has a lot of cash. Very interesting fundamental story. Technically it looks very strong as well.